No Data
No Data
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)
HC Wainwright & Co. : The Agenus (AGEN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $40.00.
HC Wainwright & Co. : The Agenus (AGEN.US) rating was reaffirmed and adjusted from buy to buy, and the target price was $40.00.
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $40 price target.
Agenus Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 230.85% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/18/2024 -58.64% B. Riley Securities $
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index adding 0.8% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%. The iShares Biotechnology ETF (IBB) fell 0.2%. In corpo
No Data